Panacea Biotec , a prominent player in the pharmaceutical industry, has announced a significant development in its business operations. The company has secured a substantial order worth approximately ₹315.00 crore (US$ 35.65 million) from the United Nations International Children's Emergency Fund (UNICEF) for the supply of bivalent oral polio vaccine (bOPV).

Key Details of the Order

Contract Specifics

Panacea Biotec received a Letter of Award from UNICEF for a Long-Term Agreement to supply bOPV. This agreement spans from April 1, 2026, to March 31, 2030. The current order value of ₹315.00 crore specifically covers the supply for Q2 CY2026 and CY2027.

The company will be supplying the bOPV in both 10 and 20 vial presentations, catering to UNICEF's requirements. The vaccine will be used for UNICEF's global polio eradication efforts.

Transparency in Award Process

As part of UNICEF's commitment to transparency, the organization will make the award public by publishing the following information on its website:

1. Supplier's name (Panacea Biotec Limited)
2. Vaccine type (bOPV)
3. Duration of the award
4. Total award value
5. Awarded prices per supplier, product presentation, and year

Impact on Panacea Biotec

This order represents a significant business opportunity for Panacea Biotec, potentially strengthening its position in the global vaccine market. The company's ability to secure such a substantial international order from a prestigious organization like UNICEF underscores its capabilities in vaccine production and quality standards.

Regulatory Compliance

Panacea Biotec has duly informed the stock exchanges about this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that this order does not fall under related party transactions, and there is no interest of promoters or group companies in UNICEF.

This order comes as positive news for Panacea Biotec, potentially boosting investor confidence and highlighting the company's role in global health initiatives, particularly in the fight against polio.

Panacea Biotec , a leading biotechnology company, has made a significant move in the Indian baby care market with the launch of two new product lines through its wholly-owned subsidiary, Panacea Biotec Pharma Limited (PBPL). The company has introduced 'NikoMom', touted as India's first 100% toxin-free baby care line, and 'Staart Prime', an infant milk substitute.

NikoMom: A New Era in Baby Skin Care

NikoMom represents a breakthrough in the baby care segment, offering a range of products designed with safety and purity at their core. The line includes:

• Baby Massage Oil
• Baby Head to Toe Wash
• Baby Daily Lotion
• Diaper Rash Cream

These products are developed using advanced technologies to cater to specific baby care needs:

• The Baby Massage Oil features 'Hydranest Technology' for muscle and bone strengthening, deep skin hydration, and enhanced skin elasticity.
• The Head to Toe Wash employs 'TenderNest Technology' for gentle cleansing while preserving skin moisture and natural oils.
• The Daily Lotion utilizes 'DermaNest Technology' for 24-hour hydration and strengthening of the skin's moisture barrier.
• The Diaper Rash Cream incorporates 'HealNest Technology' to boost cellular skin repair and prevent rash triggers.

Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec Ltd., emphasized the company's commitment to baby care, stating, "NikoMom stands for purity, safety, and innovation, ensuring that every child receives the gentlest care without toxic chemicals."

Staart Prime: Addressing Infant Nutrition

Alongside NikoMom, Panacea Biotec has launched 'Staart Prime', an infant milk substitute product. The range includes formulations for different stages of infant development:

• Staart Prime Stage 1
• Staart Prime Stages 2-3-4

Both NikoMom and Staart Prime are currently focused on the domestic Indian market, with potential international launches planned for the future.

Market Strategy and Availability

The new products will be available through various channels:

• 7NShop.com, Panacea Biotec's official e-commerce platform
• Online retailers such as Amazon, Flipkart, and Tata 1mg
• Local retailers across India

This launch aligns with Panacea Biotec's broader strategy of expanding its consumer healthcare portfolio under the '7N Panacea Biotec' brand, which focuses on science-driven, everyday healthcare solutions for families.

Company Background

Panacea Biotec has a strong presence in the biotechnology sector, with established capabilities in vaccines, pharmaceuticals, and nutrition. The company has played a significant role in polio eradication efforts, having supplied over 10 billion doses of polio vaccine in India and other developing countries.

With this latest launch, Panacea Biotec aims to leverage its expertise in healthcare to address the growing demand for safe, high-quality baby care products and infant nutrition in the Indian market.